NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage pharmaceutical company and subsidiary of SciSparc Ltd., has completed manufacturing of its investigational drug SCI-110 and obtained batch release certification from a European Qualified Person, the company announced. The certification is a regulatory prerequisite for shipping clinical trial material to study sites and represents a critical operational step toward initiating patient enrollment in the FDA-approved Phase IIb trial for Tourette Syndrome in adults.
The Phase IIb study is being conducted at three sites: Yale Child Study Center at Yale School of Medicine in New Haven, Connecticut; Hannover Medical School in Hanover, Germany; and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. According to the announcement, all participating sites have completed site initiation activities and are prepared to receive drug supplies following the Qualified Person release. Investigational product shipments are expected in the near term.
The milestone matters because Tourette Syndrome remains a condition with substantial unmet treatment needs. Current therapies often provide limited benefit or carry troublesome side effects, leaving patients and clinicians with few satisfactory options. A new drug candidate that advances into a mid-stage, FDA-approved trial signals a potential expansion of the treatment pipeline for a neurological disorder that has attracted relatively little late-stage industry investment.
SCI-110 is NeuroThera’s proprietary, patent-protected cannabinoid-based drug candidate that combines dronabinol and palmitoylethanolamide (PEA) in a single oral dosage form. The Phase IIb trial is designed to evaluate the efficacy, safety and tolerability of SCI-110 in adults with Tourette Syndrome. The completion of manufacturing and batch release, together with the completion of site initiation across all three clinical centers, positions the company to begin enrolling patients and generating the clinical data needed to assess whether the combination warrants further development.
For investors and observers of the clinical-stage biotech sector, the announcement is a reminder that drug development timelines depend heavily on manufacturing and regulatory logistics as well as on clinical outcomes. The Qualified Person release confirms that the investigational product meets the requirements for shipment under European regulatory standards, reducing a potential source of delay as the trial moves toward enrollment. The company’s progress was reported through www.newmediawire.com.
NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations. As with any clinical program, the company cautions that forward-looking statements about enrollment timing and the potential efficacy, safety and tolerability of SCI-110 are subject to risks and uncertainties. Additional information about the company and its disclosures is available on SEDAR+ at www.sedarplus.ca.
